<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03088852</url>
  </required_header>
  <id_info>
    <org_study_id>EMC 70-16</org_study_id>
    <nct_id>NCT03088852</nct_id>
  </id_info>
  <brief_title>Magnesium Deficiency In Patients Hospitalized in Internal Medicine Wards</brief_title>
  <official_title>Magnesium Deficiency In Patients Hospitalized in Internal Medicine Wards</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Frieda Wolf</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>HaEmek Medical Center, Israel</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      Hypomagnesemia is a common entity in the inpatient and outpatient setting. in previous
      retrospective study hypomagnesemic patients have higher mortality and longer hospitalization.
      whether hypomagnesemia is merely a marker of poor prognosis, or whether replacing it can
      improve outcomes is unclear. The current standard of care is to discharge these patients
      without workup or further treatment, even if patients had received intravenous therapy while
      hospitalized. The investigator wish to examine prospectively whether giving replacement
      therapy affects mortality, length of hospital stay and overall well-being. In order to
      replete intracellular levels and replete magnesium stores, magnesium should be given for
      several months.
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">May 10, 2017</start_date>
  <completion_date type="Anticipated">December 2020</completion_date>
  <primary_completion_date type="Anticipated">December 2019</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>compare mortality</measure>
    <time_frame>one year</time_frame>
    <description>To compare mortality between the population receiving magnesium and the population receiving standard care: ie no replacement.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Hospitalization</measure>
    <time_frame>one year</time_frame>
    <description>Length in days of hospitalization.</description>
  </secondary_outcome>
  <other_outcome>
    <measure>causes for hypomagnesemia</measure>
    <time_frame>one year</time_frame>
    <description>The investigators will attempt to ascertain the causes for hypomagnesemia from the data collected (medications, diarrhea, malnutrition, etc)</description>
  </other_outcome>
  <other_outcome>
    <measure>re-hospitalization</measure>
    <time_frame>one year</time_frame>
    <description>re-hospitalization for any cause</description>
  </other_outcome>
  <other_outcome>
    <measure>Subjective well-being</measure>
    <time_frame>one year</time_frame>
    <description>symptoms and overall well-being of the patients: a questionaire will be administered at the beginning of the study and at each visit regarding subjective feelings of well being, symptoms of pain, cramping and diarrhea, and overall functional capacity</description>
  </other_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">330</enrollment>
  <condition>Hypomagnesemia</condition>
  <arm_group>
    <arm_group_label>Experimental group</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>After initial intravenous treatment, participants (those with magnesium level ≥1 mg/dL) will be randomized, and oral magnesium therapy ( or no treatment) will be started. The experimental group will receive 400mg magnesium daily in two divided doses. Patients in the experimental group will be discharged with one month's supply of magnesium and continued for at least three months.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Control group</arm_group_label>
    <arm_group_type>No Intervention</arm_group_type>
    <description>control group will receive standard care (no treatment). Patient will have their blood tested and will come for follow up visit every month for 3 months after discharge.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Magnesium Citrate 100 MG</intervention_name>
    <description>initial intravenous treatment: Patients with magnesium levels 1-1.5 mg/dL will receive 2-4 grams of magnesium sulfate in the first 24 hours. Patients with magnesium levels 1.6-1.9 mg/dL will receive 1 gram of magnesium sulfate. participants with magnesium level ≥1 mg/dL, will be randomized, and oral magnesium therapy, Magnesium Citrate, ( or no treatment) will be started, and continued for at least three months. The experimental group will receive 400mg magnesium daily in two divided doses.</description>
    <arm_group_label>Experimental group</arm_group_label>
    <other_name>Diasporal</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Any patient admitted over the age of 18, has hypomagnesemia (magnesium level ≤1.9
             mg/dL) and is able to give consent.

        Exclusion Criteria:

          -  A patient unable to give consent.

          -  A patient admitted for an elective procedure.

          -  A patient in critical condition or dying.

          -  Patients with advanced kidney disease with eGFR&lt;15ml/min or on dialysis.

          -  Patients with severe diarrhea, precluding use of magnesium citrate.

          -  Patients already receiving magnesium supplements.

          -  Patients with severe malnutrition or life-threatening hypomagnesemia (serum level
             &lt;1mg/dL), requiring intravenous and oral replacement of magnesium.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>90 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Frieda Wolf</last_name>
    <role>Principal Investigator</role>
    <affiliation>haemek medical center</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Frieda Wolf</last_name>
    <phone>972-4-6495476</phone>
    <email>friedawo@clalit.org.il</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Rotem Shvartzman</last_name>
    <phone>972-4-6495351</phone>
    <email>rotem_sw@clait.org.il</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Emek Medical Center</name>
      <address>
        <city>Afula</city>
        <country>Israel</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Frieda Wolf, MD</last_name>
      <phone>972502285400</phone>
      <email>friedawolf@hotmail.com</email>
    </contact>
    <contact_backup>
      <last_name>Rotem Scwartz</last_name>
      <phone>97246495351</phone>
      <email>rotem_sw@clalit.org.il</email>
    </contact_backup>
  </location>
  <location_countries>
    <country>Israel</country>
  </location_countries>
  <reference>
    <citation>Weglicki WB. Hypomagnesemia and inflammation: clinical and basic aspects. Annu Rev Nutr. 2012 Aug 21;32:55-71. doi: 10.1146/annurev-nutr-071811-150656. Epub 2012 Mar 8. Review.</citation>
    <PMID>22404119</PMID>
  </reference>
  <reference>
    <citation>Rayssiguier Y, Libako P, Nowacki W, Rock E. Magnesium deficiency and metabolic syndrome: stress and inflammation may reflect calcium activation. Magnes Res. 2010 Jun;23(2):73-80. doi: 10.1684/mrh.2010.0208. Epub 2010 May 31. Review.</citation>
    <PMID>20513641</PMID>
  </reference>
  <reference>
    <citation>Chaigne-Delalande B, Li FY, O'Connor GM, Lukacs MJ, Jiang P, Zheng L, Shatzer A, Biancalana M, Pittaluga S, Matthews HF, Jancel TJ, Bleesing JJ, Marsh RA, Kuijpers TW, Nichols KE, Lucas CL, Nagpal S, Mehmet H, Su HC, Cohen JI, Uzel G, Lenardo MJ. Mg2+ regulates cytotoxic functions of NK and CD8 T cells in chronic EBV infection through NKG2D. Science. 2013 Jul 12;341(6142):186-91. doi: 10.1126/science.1240094.</citation>
    <PMID>23846901</PMID>
  </reference>
  <reference>
    <citation>Misra PS, Alam A, Lipman ML, Nessim SJ. The relationship between proton pump inhibitor use and serum magnesium concentration among hemodialysis patients: a cross-sectional study. BMC Nephrol. 2015 Aug 13;16:136. doi: 10.1186/s12882-015-0139-9.</citation>
    <PMID>26268579</PMID>
  </reference>
  <verification_date>March 2018</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>October 27, 2016</study_first_submitted>
  <study_first_submitted_qc>March 19, 2017</study_first_submitted_qc>
  <study_first_posted type="Actual">March 23, 2017</study_first_posted>
  <last_update_submitted>March 7, 2018</last_update_submitted>
  <last_update_submitted_qc>March 7, 2018</last_update_submitted_qc>
  <last_update_posted type="Actual">March 8, 2018</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor-Investigator</responsible_party_type>
    <investigator_affiliation>HaEmek Medical Center, Israel</investigator_affiliation>
    <investigator_full_name>Frieda Wolf</investigator_full_name>
    <investigator_title>Senior Physician in Internal Medicine C, Haemek Medical Center, Israel</investigator_title>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Magnesium Deficiency</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Citric Acid</mesh_term>
    <mesh_term>Magnesium citrate</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

